BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Rytelo (Imetelstat) readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Rytelo (Imetelstat)\, from ClinicalTrials
 .gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07549451-2864@assetmemo.bio
DTSTAMP:20261121T004029Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:Rytelo (Imetelstat): Phase 2 readout est. (NCT07549451)
DESCRIPTION:Rytelo (Imetelstat)\, phase 2.\nStudy: Phase 2 Study Of Imetels
 tat for Patient With Myelodysplastic/Myeloproliferative Neoplasms\nEstimat
 ed primary completion: 31 May 2027. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/imetelstat#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT07549451
URL:https://assetmemo.bio/drug/imetelstat#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06247787-2864@assetmemo.bio
DTSTAMP:20261121T004029Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:Rytelo (Imetelstat): Phase 1 readout est. (NCT06247787)
DESCRIPTION:Rytelo (Imetelstat)\, phase 1.\nStudy: A Study to Find the High
 est Dose of Imetelstat in Combination With Fludarabine and Cytarabine for 
 Patients With AML\, MDS or JMML That Has Come Back or Does Not Respond to 
 Therapy\nEstimated primary completion: 31 March 2028. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/imetelstat#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT06247787
URL:https://assetmemo.bio/drug/imetelstat#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07320235-2864@assetmemo.bio
DTSTAMP:20261121T004029Z
DTSTART;VALUE=DATE:20300617
DTEND;VALUE=DATE:20300618
SUMMARY:Rytelo (Imetelstat): Phase 1 readout est. (NCT07320235)
DESCRIPTION:Rytelo (Imetelstat)\, phase 1.\nStudy: Imetelstat Combinations 
 in Relapsed AML\nEstimated primary completion: 17 June 2030. This is a Cli
 nicalTrials.gov estimate\, not a confirmed readout date\, and it can move.
 \nDrug page: https://assetmemo.bio/drug/imetelstat#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT07320235
URL:https://assetmemo.bio/drug/imetelstat#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07939451-2864@assetmemo.bio
DTSTAMP:20261121T004029Z
DTSTART;VALUE=DATE:20300731
DTEND;VALUE=DATE:20300801
SUMMARY:Rytelo (Imetelstat): Phase 4 readout est. (NCT07939451)
DESCRIPTION:Rytelo (Imetelstat)\, phase 4.\nStudy: A Trial Evaluating Two I
 metelstat Doses in Participants With Lower Risk Myelodysplastic Syndrome (
 MDS)\nEstimated primary completion: July 2030. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/imetelstat#upcoming-events\nRegistry record: htt
 ps://clinicaltrials.gov/study/NCT07939451
URL:https://assetmemo.bio/drug/imetelstat#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
